Patents by Inventor Liat Dassa

Liat Dassa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-TIGIT anibodies, anti-PVRIG antibodies and combinations thereof
    Patent number: 10213505
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: February 26, 2019
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • METHOD OF PROMOTING HAIR GROWTH
    Publication number: 20180345047
    Abstract: A method of promoting hair growth or reducing hair loss in a subject is disclosed. The method comprises contacting the scalp and skin region in which there is desire for hair growth of the subject with an effective amount of at least one agent which down-regulates an activity and/or an amount of a protein selected from the group consisting of p21, Bcl-xL and Bcl-w. Compositions capable of same are also disclosed.
    Type: Application
    Filed: February 25, 2016
    Publication date: December 6, 2018
    Inventors: Valery KRIZHANOVSKY, Reut YOSEF, Noam PILPEL, Ittai BEN-PORATH, Liat DASSA, Ronit AMIEL-TOKARSKY
  • Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
    Patent number: 10124061
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: November 13, 2018
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
    Publication number: 20180305456
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Application
    Filed: August 17, 2017
    Publication date: October 25, 2018
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • HIDE1 COMPOSITIONS AND METHODS
    Publication number: 20180305451
    Abstract: According to at least some embodiments of the present invention is directed to anti-HIDE1 antibodies and polypeptides and methods of using same.
    Type: Application
    Filed: July 13, 2016
    Publication date: October 25, 2018
    Inventors: Yosef DICKEN, Liat DASSA, Amit NOVIK, Amir TOPORIK, Gad COJOCARU, Yossef KLIGER, Yair BENITA, Ofer LEVY, Ilan VAKNIN, Arthur MACHLENKIN, Iris HECHT, Jungmin KIM, Andrew POW, Andrew W DRAKE
  • POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS
    Publication number: 20180298109
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.
    Type: Application
    Filed: January 29, 2018
    Publication date: October 18, 2018
    Inventors: Anat COHEN-DAYAG, Merav BEIMAN, Liat DASSA, Marina BUBIS, Shirley SAMEACH GREENWALD, Dalit LANDESMAN-MILO, Cynthia KOIFMAN, Ofer LEVY, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Zurit LEVINE, Avi ROSENBERG, Galit ROTMAN, Eve MONTIA, Amit NOVIK, Amir TOPORIK, Shira WALACH
  • Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
    Patent number: 10098934
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: October 16, 2018
    Assignee: COMPUGEN LTD
    Inventors: Zurit Levine, Amir Toporik, Amit Novik, Anat Cohen-Dayag, Avi Rosenberg, Cynthia Koifman, Dalit Landesman-Milo, Eve Montia, Galit Rotman, Liat Dassa, Marina Bubis, Merav Beiman, Ofer Levy, Sergey Nemzer, Shira Walach, Shirley Sameach- Greenwald, Tania Pergam, Yaron Kinar
  • ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
    Publication number: 20180280506
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Application
    Filed: March 27, 2018
    Publication date: October 4, 2018
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • ANTI-PVRIG ANTIBODIES AND METHODS OF USE
    Publication number: 20180244774
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Application
    Filed: February 13, 2018
    Publication date: August 30, 2018
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
    Publication number: 20180169238
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Application
    Filed: October 26, 2017
    Publication date: June 21, 2018
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • C10RF32 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER
    Publication number: 20170233473
    Abstract: This invention relates to C1ORF32-specific antibodies, antibody fragments, alternative scaffolds, conjugates and compositions comprising same, for treatment of cancer.
    Type: Application
    Filed: February 28, 2017
    Publication date: August 17, 2017
    Applicant: Compugen Ltd.
    Inventors: Gady S. COJOCARU, Galit ROTMAN, Zurit LEVINE, Liat DASSA, Ofer LEVI, Raffaella BRIANTE, Shweta SINGH, Susan R. WATSON, Tania PERGAM
  • Anti-PVRIG antibodies and methods of use
    Patent number: 9714289
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: July 25, 2017
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS
    Publication number: 20170107284
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KRTCAP3, FAM26F, MGC52498, FAM70A or TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages. This invention further relates to extracellular domains of KRTCAP3, FAM26F, MGC52498, FAM70A and TMEM154 proteins and variants, and therapeutic usages thereof.
    Type: Application
    Filed: November 29, 2016
    Publication date: April 20, 2017
    Inventors: Amir TOPORIK, Amit NOVIK, Anat COHEN-DAYAG, Avi Yeshah ROSENBERG, Eve MONTIA, Galit ROTMAN, Liat DASSA, Merav BEIMAN, Ofer LEVY, Shira WALACH, Shirley SAMEACH- GREENWALD, Yaron KINAR, Zurit LEVINE, Gad S. COJOCARU, Sergey NEMZER
  • C10RF32 antibodies, and uses thereof for treatment of cancer
    Patent number: 9617336
    Abstract: This invention relates to C1ORF32-specific antibodies, antibody fragments, alternative scaffolds, conjugates and compositions comprising same, for treatment of cancer.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: April 11, 2017
    Assignee: COMPUGEN LTD
    Inventors: Gady S. Cojocaru, Galit Rotman, Zurit Levine, Liat Dassa, Ofer Levi, Raffaella Briante, Shweta Singh, Susan R. Watson, Tania Pergam
  • PVRIG POLYPEPTIDES AND METHODS OF TREATMENT
    Publication number: 20170088607
    Abstract: The present invention is directed to PVRIG polypeptides and their uses.
    Type: Application
    Filed: February 19, 2016
    Publication date: March 30, 2017
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad. S. Cojocaru, Amir Toporik, Yossef Kliger, Ofer Levy, Arthur Machlenkin, Sergey Nemzer, Yair Benita, Amit Novik
  • ANTI-PVRIG ANTIBODIES AND METHODS OF USE
    Publication number: 20170081408
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Application
    Filed: September 27, 2016
    Publication date: March 23, 2017
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru
  • POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS
    Publication number: 20170037141
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.
    Type: Application
    Filed: January 30, 2016
    Publication date: February 9, 2017
    Inventors: Anat COHEN-DAYAG, Merav BEIMAN, Liat DASSA, Marina BUBIS, Shirley SAMEACH- GREENWALD, Dalit LANDESMAN-MILO, Cynthia KOIFMAN, Ofer LEVY, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Zurit LEVINE, Avi ROSENBERG, Galit ROTMAN, Eve MONTIA, Amit NOVIK, Amir TOPORIK, Shira WALACH
  • ANTI-PVRIG ANTIBODIES AND METHODS OF USE
    Publication number: 20170029504
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Application
    Filed: September 27, 2016
    Publication date: February 2, 2017
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru
  • Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
    Patent number: 9555087
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: January 31, 2017
    Assignee: COMPUGEN LTD
    Inventors: Amir Toporik, Amit Novik, Anat Cohen-Dayag, Avi Yeshah Rosenberg, Cynthia Koifman, Dalit Landesman-Milo, Eve Montia, Galit Rotman, Liat Dassa, Marina Bubis, Merav Beiman, Ofer Levi, Sergey Nemzer, Tania Pergam, Yaron Kinar, Shirley Sameach- Greenwald, Zurit Levine, Shira Walach
  • VSTM5 POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES
    Publication number: 20160347814
    Abstract: This invention relates to VSTM5 proteins, soluble molecules and fusions thereof which are suitable targets for drug development and for treatment of immune related disorders, immunotherapy, treatment of cancer, infectious disorders and/or sepsis.
    Type: Application
    Filed: March 10, 2016
    Publication date: December 1, 2016
    Inventors: Zurit LEVINE, Galit ROTMAN, Liat DASSA, Ofer LEVY, Gad S. COJOCARU, Amir TOPORIK, Yossef KLIGER, Ilan VAKNIN, Iris HECHT